TG Therapeutics Q2 EPS $(0.34) Misses $(0.25) Estimate, Sales $16.07M Miss $17.45M Estimate
Portfolio Pulse from Benzinga Newsdesk
TG Therapeutics reported Q2 losses of $0.34 per share, missing the analyst consensus estimate of $0.25 by 36%. This is a 13.33% decrease over losses from the same period last year. The company also reported quarterly sales of $16.07M, missing the analyst consensus estimate of $17.45M by 7.89%. This is a 2.61K% increase over sales from the same period last year.
August 01, 2023 | 11:36 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
TG Therapeutics reported lower than expected Q2 earnings and sales, which could negatively impact the stock price in the short term.
TG Therapeutics reported both lower than expected earnings per share and sales for Q2. This underperformance could lead to a decrease in the stock price as it indicates the company may be struggling to meet financial targets.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100